Uncover the Biological Nuances of Gamma Delta T Cells to Inform your Translational Strategy including Targeting Specificity, Combination Strategies & Product Development to Confidently Progress to Clinical & Scalable Development for Patients in Need
Welcome to the 5th Gamma Delta T Cell Therapies Summit
The Only Industry Gamma Delta T Cell-Specific Meeting Running This Year
Gamma Delta T cells prove an exciting platform for the treatment of solid tumor indications and autoimmune disorders. The unique biology of these cells is revolutionizing the development of allogeneic therapies.
The 5th Gamma Delta T Cell Therapies Summit returns to take a deep dive into the biological intricacies of gamma delta T cells, deciphering the rich landscape of targeted interventions and engineering, and exploit their unique pathways and mechanisms to create more effective therapeutics.
- Upskill cross-functional teams across discovery, translation and clinical development skills, to successfully translate basic research into your clinical strategy to support upcoming IND submissions.
- Deep dive into everything from exploring past and present clinical trial data, new epigenetic reprogramming of gamma delta T cells, Neoadjuvants and Adjuvants, and lessons learned when manufacturing gamma delta T cells at a clinical scale.
- Be the first to hear about unpublished new data from Moffitt Cancer Center on their allogeneic gamma delta immunotherapy for AML and new clinical data updates from IN8Bio and Adicet Bio.
Want to Know Why
You Should Attend in 2024?
We Collaborated With IN8Bio, Adicet Bio, Acepodia, Takeda, Luminary Therapeutics, LAVA Therapeutics, OneChain Therapeutics
Bringing together experts from big pharma, biotech and academia to delve into the details of gamma delta biology and its various subsets to offer the audience a well-rounded overview of the landscape currently and the steps needed for it to move forward.
With a world-class speaker faculty, this meeting continues to be the one-stop shop to accelerate your gamma delta T therapies.
2024 Speaker Faculty Includes:
Antara Banerjee
Senior Director, Head Cell Engager Therapies, Oncology Drug Discovery Unit
Takeda Pharmaceutical Co. Ltd.
Our 2024 Partners:
Companies Attending Include:
